Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | BRAF F595L |
| Therapy | Cetuximab + Trametinib |
| Indication/Tumor Type | intrahepatic cholangiocarcinoma |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| BRAF F595L | intrahepatic cholangiocarcinoma | predicted - sensitive | Cetuximab + Trametinib | Case Reports/Case Series | Actionable | In a clinical case study, treatment with the combination of Erbitux (cetuximab) and Mekinist (trametinib) followed by Erbitux (cetuximab) monotherapy resulted in an objective response at a follow-up of 6 months in a patient with intrahepatic cholangiocarcinoma harboring BRAF F595L along with an IDH2 R172W (PMID: 39516363). | 39516363 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (39516363) | Therapeutic vulnerabilities and pan-cancer landscape of BRAF class III mutations in epithelial solid tumors. | Full reference... |